Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Whelton

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
American Journal of Therapeutics|June 22, 2010
Current and future therapeutic options for the management of goutAndrew Whelton
Hypertension (Dallas, Tex. : 1979)|September 26, 2012
Hyperuricemia and hypertension: a confluence of conceptsAndrew Whelton
American Journal of Therapeutics|November 16, 2004
The coxib conundrum: lessons from the rise and fall of rofecoxibAndrew Whelton
The American Journal of Cardiology|May 6, 2006
Clinical implications of nonopioid analgesia for relief of mild-to-moderate pain in patients with or at risk for cardiovascular diseaseAndrew Whelton
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|April 10, 2003
COX-2-specific inhibitors and the kidney: effect on hypertension and oedemaAndrew Whelton
American Journal of Therapeutics|November 5, 2010
Minimizing cardiovascular complications during the treatment of osteoarthritisAndrew Whelton, Allan Gibofsky
American Journal of Therapeutics|December 1, 1994
A Study Design for Comparing the Effects of Missing Daily Doses of Antihypertensive DrugsBrian F. Johnson, Andrew Whelton
American Journal of Therapeutics|November 1, 1995
Effects of Misoprostol on Nonsteroidal Anti-Inflammatory Drug-Induced Renal Insufficiency in Patients with Stable Chronic Renal Failure: A Double-Blind, Crossover StudyAndrew Whelton, Henry Scott, Robert L. Stout
American Journal of Therapeutics|July 1, 1996
Atheroembolic Renal DiseaseJoseph A. Vassalotti, Fernando A. Delgado, Andrew Whelton
American Journal of Therapeutics|February 17, 2007
Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugsWilliam M Spalding, Mathew J Reeves, Andrew Whelton
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
American Journal of Therapeutics|June 22, 2010
Current and future therapeutic options for the management of goutAndrew Whelton
Hypertension (Dallas, Tex. : 1979)|September 26, 2012
Hyperuricemia and hypertension: a confluence of conceptsAndrew Whelton
American Journal of Therapeutics|November 16, 2004
The coxib conundrum: lessons from the rise and fall of rofecoxibAndrew Whelton
The American Journal of Cardiology|May 6, 2006
Clinical implications of nonopioid analgesia for relief of mild-to-moderate pain in patients with or at risk for cardiovascular diseaseAndrew Whelton
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|April 10, 2003
COX-2-specific inhibitors and the kidney: effect on hypertension and oedemaAndrew Whelton
American Journal of Therapeutics|November 5, 2010
Minimizing cardiovascular complications during the treatment of osteoarthritisAndrew Whelton, Allan Gibofsky
American Journal of Therapeutics|December 1, 1994
A Study Design for Comparing the Effects of Missing Daily Doses of Antihypertensive DrugsBrian F. Johnson, Andrew Whelton
American Journal of Therapeutics|November 1, 1995
Effects of Misoprostol on Nonsteroidal Anti-Inflammatory Drug-Induced Renal Insufficiency in Patients with Stable Chronic Renal Failure: A Double-Blind, Crossover StudyAndrew Whelton, Henry Scott, Robert L. Stout
American Journal of Therapeutics|July 1, 1996
Atheroembolic Renal DiseaseJoseph A. Vassalotti, Fernando A. Delgado, Andrew Whelton
American Journal of Therapeutics|February 17, 2007
Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugsWilliam M Spalding, Mathew J Reeves, Andrew Whelton
Pageof 4